Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Opus Genetics, Inc. (IRD)
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. Collaborative Community on Ophthalmic Innovation (CCOI) Topic: Opus Genetics leadership will participate in discussions focused on emerging treatment approaches and clinical insights in retinal disease.Date: February 3-4, 2026Location: Hong Kong Asia-Pacific Academy of Ophthalmology Congress (APAO) Topic: The Company will engage with the global ophthalmology community to discuss advances in gene therapy and evolving strategies for treating inherited retinal disorders.Date: February 5-8, 2026Location: Hong Kong Advanced Therapies Week Conference Title: Buildi
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.MarketBeat
- Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis PigmentosaGlobeNewswire
- Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
- Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
- Opus Genetics Highlights 2025 Progress and Upcoming 2026 CatalystsGlobeNewswire
IRD
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- IRD's page on the SEC website